Clinical Trial

Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 1, 2024 (before its estimated February 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to assess the safety and efficacy of QHRD107 capsule combined with Venclexta and azacitidine in the treatment of relapsed/refractory acute myeloid leukemia: a single-arm, open, multicenter Phase IIa study
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06532058
Lead Sponsor Changzhou Qianhong Bio-pharma Co., Ltd.
Conditions Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML)
Enrollment 53 participants
Start Date 2023-08-10
Primary Completion 2025-02-10 (estimated)
Study Completion 2025-05-10 (estimated)
Updated on ClinicalTrials.gov 2024-08-01